KeyPoint Subvention
frenfr
← Back to the blog
CIR

Are clinical trials eligible for the CIR? Phase by phase

· By David Jian, Partner and Certified Public Accountant, KeyPoint International

Rows of blood collection tubes with coloured caps in a laboratory rack
Photo: Testalize.me / Unsplash

Short answer

Mostly yes. Phases 1, 2 and 3 are accepted as research by convention, so they qualify for France's research tax credit (the CIR, or crédit d'impôt recherche). To the quiet relief of everyone who would otherwise argue it annually, that convention spares the whole pre-market programme. Everything turns on what happens once the medicine reaches the market.

A phase 4 trial that intervenes, comparing a treated group against a control to answer an open scientific question, can qualify. A phase 4 study that only observes, covering routine safety monitoring and real-world effectiveness, falls outside.

However, two set-ups are excluded whatever the phase. Both are common enough that you should check them before you budget for the credit and talk to a specialised advisor like KeyPoint Subvention.

Where the line falls, phase by phase

PhaseWhat it doesCIR
Pre-clinicalStudies the molecule, its structure and its effect on cells and an animal model, and sets the first safe human doseEligible
Phase 1Tolerance and side effects, usually in 20 to 80 healthy paid volunteers, plus kinetics and metabolism in humansEligible
Phase 2Optimal dose and side effects in patients: 2a estimates efficacy in 100 to 200 patients, 2b sets the therapeutic dose in 100 to over 300Eligible
Phase 3The comparative efficacy study proper, against a placebo or a reference treatment, often several thousand participantsEligible
Phase 4, interventionalCompares a treated group against a control to lift a scientific obstacle, or tests the medicine under particular conditions of useCase by case
Phase 4, observationalLong-term follow-up once the medicine is authorised: rare side effects, real-world effectivenessNot eligible

Phases 1 to 3 all precede marketing authorisation (autorisation de mise sur le marché, or AMM). Running them requires clearance from the French medicines agency (ANSM) and a favourable opinion from an ethics committee (comité de protection des personnes, or CPP), and each trial carries a European registration number (a EudraCT number, or, for trials registered since 2023, its successor in the EU Clinical Trials Information System, or CTIS). The guide published by the ministry for higher education and research treats these three phases as research by convention, which is why they rarely generate an argument.

The phase 4 distinction, and how to tell which you have

After authorisation, the paperwork tells you which side of the line you are on. An observational study needs only a declaration to the medicines agency plus the ethics committee's opinion, and it carries an ID-RCB number. Those studies exist to spot rare adverse effects or to measure real-world effectiveness, and the guide places them outside research.

Interventional phase 4 trials carry risk for the volunteers, so they need full agency authorisation and a favourable ethics opinion, and they get the same European registration number as phases 1 to 3. Where such a trial sets out to lift a scientific obstacle, it can be treated as research, subject to an analysis of how it was run.

There is one narrow exception for observational work. The ministry's experts may accept a phase 4 observational study case by case, where it produced something that counts as a strong research indicator. The example the guide gives is publication in a very high-level journal: the Lancet, Nature Medicine, JAMA or the New England Journal of Medicine. Treat that as the exception it is.

Not sure which side your programme sits on? Our CIR eligibility test walks through the criteria in two minutes, with no sign-up. → Take the CIR eligibility test

Two exclusions that catch sponsors out

Trials you sponsor for someone else. Investigator-sponsored trials and investigator-sponsored studies, the ones a company funds while an outside investigator runs them, are not eligible for the CIR at all. They may instead give rise to a reduction under the corporate philanthropy rules (mécénat), which is a different calculation on a different form.

Support staff. Clinical work involves a long list of roles, and only those directly involved in the scientific investigation count for R&D tax incentives from the French Government. Support staff are expressly outside the scheme. Note that for everyone you do claim, you or your adviser will need to evidence the competence, either by the relevant qualification or by showing the skills were acquired in practice.

The same rules apply to veterinary medicine. Trials run before the marketing authorisation can be research; afterwards they face the same test as epidemiological studies beyond phase 3.

What actually evidences the research

Publications, supervising a thesis including under an industrial research training agreement (CIFRE), scientific collaborations with public bodies, subsidised collaborative projects, and patent or software filings all help. The guide calls them research indicators and is careful about what they prove: their presence does not make an operation eligible, and their absence is not fatal. Where you have one, attach it to the file as a short summary or a link, and tell your adviser it is there.

Patents deserve a caveat of their own. A patent can evidence novelty and creativity, two of the five criteria. It says nothing about uncertainty, systematic approach or reproducibility, and the Conseil d'État has held that filing one does not imply research was needed (decision of 13 November 2013, no. 341432). For example, a patent on a formulation does not carry the trial that tested it. You, or your adviser drafting the file, still have to explain the scientific link between the patent and the operation.

The part that matters for a clinical-stage company

Most companies running trials are loss-making, and the CIR still works for them. Where there is no tax to set it against, it becomes a claim on the State. Small and medium-sized companies, and those holding young innovative company status (jeune entreprise innovante, or JEI), can have it refunded immediately. Everyone else waits three years. For a biotech between funding rounds that is a critical cash flow question, so plan accordingly.

Note that the refund is a separate step. The credit is declared on form 2069-A-SD with the corporate tax balance, due the 15th of the fourth month after year end. For a 31 December year end a derogation moves that balance to 15 May. The repayment is claimed on form 2573-SD. In practice that makes March to June the busy stretch for your accountants, and the preceding autumn the time to get the technical file written while the teams still remember the trials.

If you hold JEI status, the payroll exemption runs on the same research staff, so model the two together.

Frequently asked questions

Are pre-clinical studies eligible for the CIR? Yes. Pre-clinical work on the molecule, its effects on cells and on an animal model, and the determination of the first safe human dose, sits inside the research phase.

Is pharmacovigilance eligible? No. Regulatory pharmacovigilance is observational phase 4 work, designed to detect rare adverse effects once the medicine is on the market, and the guide places it outside research.

We fund a trial an outside investigator runs. Can we claim? Not under the CIR. Investigator-sponsored trials and studies are excluded. Ask your adviser to look at the corporate philanthropy reduction instead, which is a separate regime on a separate form.

Does a EudraCT or CTIS number prove our trial is eligible? It tells you the trial is interventional, which is the first condition after phase 3. An interventional phase 4 trial is still assessed on how it was actually run.

Talk to us

If you would like to inquire about your case in France to local experts, feel free to contact KeyPoint International - we are supporting foreign businesses in France in their incorporation and success since 2003.

This article reflects the law and the government guide as at 27 October 2026. It is not advice on a specific situation.